To the Editor : We read with interest the manuscript by Carroccio et al. ( 1 ) , in which the authors try to delimit the diagnostic criteria of a novel entity, the non-celiac wheat sensitivity (NCWS), in patients mislabelled as suff ering from irritable bowel syndrome (IBS). Th is disorder is split into two subtypes: wheat sensitivity (WS), clearly overlapping with celiac disease (CD), and multiple food sensitivity. Th e most noteworthy fi nding is the detection of duodenal and colonic eosinophilic infl ammation in patients with wheat-dependent symptoms not fulfi lling diagnostic criteria for CD. However, the defi nition for CD in this study might be controversial.
Th e authors excluded CD upon negative serum antibodies and the absence of villous atrophy in histology. In all, 94 % of NCWS patients presented with lymphocytic enteritis (LE; > 25 CD3 + intraepithelial lymphocites / 100 epithelial cells), which represents Marsh I grade in the Marsh-Oberhuber classifi cation ( 2 ) . Interestingly, 75 % in the WS group had HLA haplotypes and 30 % had positive anti-endomysium antibodies culture in biopsies. As recent evidence and consensus guidelines ( 3, 4 ) have stressed that CD is likely in Marsh I patients with either typical immunohistochemical changes or mucosal deposit of specifi c antibodies, it is conceivable that this 30 % of patients in the WS group should have been classifi ed as CD. A defi nitive diagnosis for the remaining seronegative LE patients with HLA haplotypes is uncertain. Clinicohistological re-evaluation on gluten-free diet (GFD) could have been helpful, but the retrospective design of the study limits drawing any conclusion. In agreement with other authors ( 5 ), we believe that CD can be absolutely precluded without HLA-DQ2 / HLA-DQ8 haplotypes or with HLA heterodimers and normal duodenal biopsy (Marsh 0).
Notwithstanding LE has been considered an asymptomatic mild enteropathy within CD, this concept has evolved seeing as LE may induce similar symptoms and complications than in those with villous atrophy ( 6 ) and clinicopathological remission can be achieved on GFD ( 3, 6 ) . Th us, a proper defi nition of CD, including minor subtypes, is crucial to avoid mislabelling patients previously misdiagnosed for having IBS. To the Editor: We thank the Work Group of the Spanish Gastroenterology Association for their interest and the comments about our work ( 1 ) . We fully agree with their opinion that a subgroup of patients who fulfi ll the current criteria for gluten sensitivity (GS) could actually suff er from celiac disease (CD). Th e presence of villous atrophy and positive CD-specifi c serum antibodies cannot be considered mandatory for CD diagnosis; furthermore, it is known that less severe intestinal histology damage is more frequently associated with a negative serology. Despite the negativity of the CD-specifi c serum antibodies and the absence of villous atrophy, we demonstrated that symptomatic patients who produced anti-endomisyum antibodies (EmA) in the duodenal mucosa culture can subsequently develop villous atrophy when remaining on a gluten-containing diet ( 2,3 ) and identical fi ndings have been reported for serum EmA-positive patients with an initial evaluation of normal duodenal histology ( 4 ), as well as for patients without villous atrophy but immunohistochemical evidence of anti-transglutaminase deposits in the duodenal mucosa ( 5 ).
CONFLICT OF INTEREST
Our study recently published in American Journal of Gastroenterology refl ects our clinical practice; we regularly performed HLA determination and duodenal sample culture to search for EmAs in the culture medium, in all patients with elevated clinical suspicion of CD diagnosis (family members of CD patients, coexistence of autoimmune diseases, self-reported " sure " relationship between gluten ingestion and symptoms onset, etc.), despite an initial evaluation that showed negative CD serum antibodies. In this way, however, our study found that only 22 of 276 patients (8 % ) showed positive EmAs in the culture medium of the duodenal biopsies, which we consider the strongest clue of CD in this very diffi cult diagnostic category.
On the other hand, a " simple " duodenal lymphocytosis (Marsh 1 histology), in the absence of positivity of serum CD-specifi c antibodies, cannot be considered diagnostic for CD. All " CD experts " view a Marsh 1 histology with caution. A prospective study ( 6 ) revealed that only 16 % of the patients, who underwent duodenal biopsy for suspected CD and showed lymphocytic duodenosis, actually suff ered from CD; lymphocytic duodenosis was most commonly associated with drugs (21 % ) and infection (19 % ).
In conclusion, we would underline that the main histology characteristic of the patients we studied was the eosinophil infi ltrate in the duodenal and colon mucosa: this could be the GS " marker " in most of the patients. However, the evidence that GS includes patients with very diff erent clinical, serologic, and histology characteristics -probably diff erent subgroups with diff erent disease pathogenesis -is actually the basis of our ongoing studies.
